BioPorto Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	1.4yrs
Promedio de permanencia en la Junta Directiva	10.3yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

BioPorto no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Lars Uttenthal	Chief Scientific Officer	no data	sin datos	sin datos
Gry Larsen	Executive VP & Chief Legal Officer	less than a year	sin datos	sin datos
Jennifer Zonderman	SVP of Global Marketing & US Commercialization	5yrs	sin datos	sin datos
Nis Kruse	Executive VP of Strategic Partnerships and GM of EMEA & APAC	1.4yrs	sin datos	sin datos

1.4yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 2P4 no se considera experimentado ( 0.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Donnie Hardison	Independent Vice Chairman of the Board	3.1yrs	kr.795.00k	sin datos
John McDonough	Independent Chairman of the Board	3.1yrs	kr.1.08m	0.046% DKK 41.7k
Claudio Ronco	Member of Scientific Advisory Board	10.3yrs	sin datos	sin datos
Mats Thoren	Director	no data	sin datos	sin datos
Jean-Louis Vincent	Chairman of the Scientific Advisory Board	10.3yrs	sin datos	sin datos
Henrik Juuel	Director	no data	sin datos	sin datos
Ninfa Saunders	Independent Director	1.1yrs	kr.458.00k	sin datos
Michael Singer	Independent Director	4.8yrs	kr.674.00k	0.055% DKK 49.9k
Andrew Lewington	Vice Chairman of Scientific Advisory Board	10.3yrs	sin datos	sin datos
Laurent Jacob	Member of Scientific Advisory Board	10.3yrs	sin datos	sin datos
Michael Haase	Member of Scientific Advisory Board	10.3yrs	sin datos	sin datos
Hilde Geus	Member of Scientific Advisory Board	10.3yrs	sin datos	sin datos

10.3yrs

Permanencia media

60.5yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 2P4 son experimentados ( 10.3 años antigüedad media).

BioPorto Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

BioPorto A/S Announces CEO Changes

BioPorto A/S, Annual General Meeting, Apr 30, 2024

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Bioporto A/S Announces Resignation of Neil Goldman as CFO

Recent updates

Bioporto A/S Provides Revenue Guidance for 2024

First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

Full year 2023 earnings released: kr.0.16 loss per share (vs kr.0.24 loss in FY 2022)

BioPorto A/S Announces CEO Changes

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

New major risk - Share price stability

BioPorto A/S announced that it has received $0.11 million in funding

Second quarter 2023 earnings released: kr.0.06 loss per share (vs kr.0.05 loss in 2Q 2022)

BioPorto A/S Maintains Earnings Guidance for the Year 2023

New minor risk - Shareholder dilution

High number of new and inexperienced directors

First quarter 2023 earnings released: kr.0.05 loss per share (vs kr.0.06 loss in 1Q 2022)

BioPorto A/S Maintains Financial Guidance for 2023

Full year 2022 earnings released: kr.0.24 loss per share (vs kr.0.21 loss in FY 2021)

BioPorto A/S to Report Q1, 2023 Results on May 10, 2023

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

Third quarter 2022 earnings released

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings released

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S

BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director

BioPorto A/S Maintains its Earnings Guidance for the Year 2022

Less than half of directors are independent

Full year 2021 earnings released: kr.0.21 loss per share (vs kr.0.30 loss in FY 2020)

BioPorto A/S Provides Earnings Guidance for the Full Year 2022

Third quarter 2021 earnings released: kr.0.04 loss per share (vs kr.0.087 loss in 3Q 2020)

Second quarter 2021 earnings released: kr.0.051 loss per share (vs kr.0.077 loss in 2Q 2020)

BioPorto A/S Maintains Earnings Guidance for the Year 2021

BioPorto A/S Provides Pipeline Update Regarding COVID-19 Test

First quarter 2021 earnings released: kr.0.06 loss per share (vs kr.0.088 loss in 1Q 2020)

BioPorto A/S Provides Earning Guidance for the Year 2021

Independent Vice Chairman Torben Nielsen has left the company

Independent Director has left the company

Full year 2020 earnings released: kr.0.30 loss per share (vs kr.0.41 loss in FY 2019)

Bioporto A/S Provides Earnings Guidance for the Year 2021

BioPorto Provides Pipeline Update

New 90-day high: €0.66

Revenue misses expectations

Third quarter 2020 earnings released: kr.0.09 loss per share

BioPorto A/S, Annual General Meeting, Apr 29, 2021

BioPorto A/S has completed a Follow-on Equity Offering in the amount of DKK 106.632762 million.

BioPorto A/S Plans Initial Clinical Evaluation of Grad-Based Test for Rapid Detection of COVID-19 Virus

New 90-day low - €0.28

Earnings released

New 90-day low - €0.30

CEO

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad